• Image attribution tooltip
    Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.

    Medtronic completes Intersect acquisition following FTC order

    The Federal Trade Commission required Medtronic to divest a subsidiary of Intersect ENT to complete the deal. Medtronic announced the $1.1 billion acquisition last August.

    By Updated May 16, 2022
  • Image attribution tooltip
    choness via Getty Images

    Digital health funding dropped in Q1 to lowest level since 2020: CB Insights

    The report is directionally in line with the findings of an earlier report from Rock Health, which described how the drying up of deals in February and March may be an early sign of a correction in digital health venture capital funding.

    By April 14, 2022
  • Explore the Trendline
    Image attribution tooltip
    Permission granted by Roy Mendiola

    MedTech Dive Outlook 2022

    The pandemic continues to disrupt the medical device industry early in 2022, as COVID-19 testing demand remains strong and nonemergent procedures are postponed. In this series, we look at the risks, challenges and opportunities ahead.

    By MedTech Dive staff
  • Image attribution tooltip
    E+ via Getty Images

    'Interesting anomaly': Hospital M&A fell to record low in Q1

    Hospital M&A activity in the first quarter bucked last year's trends as both the amount and size of deals shrank, according to Kaufman Hall.

    By Hailey Mensik • April 11, 2022
  • Illumina sues Guardant CEOs over trade secrets, sparking counterblast against 'retaliatory' lawsuit

    Guardant called the lawsuit "frivolous and retaliatory" and framed it as a response to its concerns about the Illumina-Grail merger.

    By March 18, 2022
  • Image attribution tooltip
    Permission granted by Akili Interactive

    Akili plans to go public as it prepares to market video game treatment

    "We've proven that foundation and now it's time to run and scale," CEO Eddie Martucci told MedTech Dive. The company is going public through a $1 billion SPAC, rather than a traditional IPO, which it expects to close in mid-2022.   

    By March 10, 2022
  • DOJ moves forward with suit to block UnitedHealth's acquisition of Change

    The lawsuit alleges that if UnitedHealth acquired Change, the payer would be able to gain a competitive advantage by seeing "very competitively sensitive" data from other insurers.

    By Shannon Muchmore • Feb. 25, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    What does a more aggressive M&A approach mean for J&J's devices unit?

    After medical device deals took off last year, one of the industry's biggest companies could make a splash in the sector in 2022.

    By , Feb. 22, 2022
  • Image attribution tooltip
    Delmaine Donson via Getty Images

    Diagnostics M&A expected to be strong in 2022 after dealmaking took off last year

    Respondents to KPMG's survey predict that deal volumes and values for the diagnostics space will jump again this year as companies are ready to spend more of their COVID-19 cash.

    By Feb. 16, 2022
  • Image attribution tooltip
    Permission granted by Johnson & Johnson

    J&J's DePuy Synthes buys ortho company CrossRoads Extremity Systems

    The deal, for an undisclosed amount, comes just weeks after Johnson & Johnson executives said the company will have a more aggressive M&A strategy going forward for the pharmaceutical and medical devices businesses.

    By Feb. 10, 2022
  • Image attribution tooltip
    JohnnyGreig via Getty Images

    Healthcare staffing shortages a 'rising concern' for medtechs: Moody's

    In a recent quarterly report, Moody's Investors Service called out hospital labor shortages as having a potential material impact on procedures in 2022, even as the omicron surge begins to decline.

    By Feb. 9, 2022
  • Image attribution tooltip
    alvarez via Getty Images
    Deep Dive

    4 key trends for procedure-reliant medtechs in 2022

    Medical device companies likely will face the same challenges this year that they have been dealing with since the pandemic's start, such as procedure volatility and hospital staffing shortages.

    By Jan. 27, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J's device recovery slowed by omicron surge, with impact expected over next several months

    CFO Joseph Wolk said that the medtech giant expects pressure from COVID-19 and hospital staffing shortages to continue through the first half of 2022, with businesses recovering month by month.

    By Jan. 25, 2022
  • Image attribution tooltip
    choness via Getty Images

    Medtech M&A, IPOs hit new highs as more buyers enter the space: SVB

    In a new report, Silicon Valley Bank projects that medical device mergers and acquisitions "will stay hot, as a diverse set of acquirers compete for the top deals," but sees a slowdown in initial public offering activity.

    By Jan. 14, 2022
  • Medtronic CEO: Company on track to hit guidance, omicron impact 'uncertain'

    Geoff Martha, who spoke on the opening day of J.P. Morgan's healthcare conference, said the medtech is being impacted by both the delta and omicron variants, including ongoing pressure from hospital staffing shortages.

    By Jan. 10, 2022
  • Wall Street backs Stryker-Vocera strategic fit but split on valuation

    The nearly $3 billion buy values Vocera at about 11.5 times higher than expected 2022 revenue, leading some analysts to question the overall price.

    By Updated Jan. 7, 2022
  • Image attribution tooltip
    Zhanna Hapanovich via Getty Images

    Medtech's biggest deals in 2021 and what to expect next

    After dealmaking took off last year following a 2020 lull, market watchers anticipate robust M&A ahead in 2022 as companies pursue faster growth and greater scale. 

    By Jan. 4, 2022
  • Image attribution tooltip
    Permission granted by Quidel Corporation

    Quidel to buy Ortho Clinical Diagnostics in $6B deal; stock tanks

    CEO Doug Bryant said the combined company will have a "broader geographic footprint" thanks to Ortho's reach across 130-plus countries. Quidel's shares fell by as much as 17.8% in Thursday morning trading.

    By Dec. 23, 2021
  • Cerner acquired by Oracle for $28B

    The deal further pushes Oracle into the healthcare market, where its presence is mostly in data use efficiency for payers and providers. Oracle's areas of focus include database software and cloud systems.

    By Shannon Muchmore • Dec. 21, 2021
  • Image attribution tooltip
    Permission granted by Johnson & Johnson

    J&J device chief on company split, omicron surge, robotic surgery

    Ashley McEvoy is confident that 2022 will not be as bad as the first or second year of the COVID-19 pandemic, even as the omicron variant drives cases up, but adds that "we're not out of the woods yet."

    By Dec. 20, 2021
  • Image attribution tooltip
    E+ via Getty Images

    Flurry of doctor group buyouts helps fuel 'extraordinary' surge in health M&A

    Companies across the healthcare spectrum are pursuing deals to strengthen operations after two years of pandemic-driven challenges, a PwC report found.

    By Dec. 14, 2021
  • Roundup: Baxter completes $10.5B Hillrom acquisition

    Wall Street analysts have questioned the price and strategic fit of the deal, which is the largest medtech buy so far in 2021.

    Dec. 14, 2021
  • Image attribution tooltip
    Permission granted by iRhythm Technologies

    New iRhythm CEO talks Medicare pricing, larger medtech competitors, international markets

    "I think the near-term noise is something that we'll work through, but the underlying technology has never been questioned," Quentin Blackford told MedTech Dive.

    By Nov. 19, 2021
  • Image attribution tooltip
    Photo courtesy of Stryker

    Stryker dismisses robotics threat from J&J, Zimmer with bullish forecast

    CEO Kevin Lobo said during Thursday's analyst day that the company is "poised and ready to pounce" if valuations fall as Stryker looks to leverage M&A in long-term growth plans.

    By Nov. 19, 2021
  • Siemens Healthineers projects revenue jump fueled by Varian double-digit sales growth

    The medtech expects its $16.4 billion Varian acquisition to post annual sales growth from 2023 to 2025, leading it to forecast accelerating revenue rises.

    By Nov. 17, 2021
  • Image attribution tooltip
    400tmax via Getty Images

    Globus in takeover talks with NuVasive to boost spine portfolio: reports

    Truist Securities and Piper Sandler analysts said the deal is unlikely. J.P. Morgan cautioned that earlier orthopaedic takeovers struggled to generate returns.

    By Nov. 16, 2021